Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P16104 (
H2AX
)
3,930
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
INPP4B
has been recently shown to be a poor prognostic marker and confer chemo- or radio-resistance in AML cells, whereas, the underlying mechanisms remain unclear. Herein, we aimed to explore the possible mechanisms mediated the resistance to chemotherapy in AML. We found that
INPP4B
-mediated resistance to genotoxic drug, cytarabine, was accompanied by lower p-
H2AX
accumulation in KG-1 cells, and
INPP4B
knockdown evidently sensitized KG-1 cells to cytarabine, meanwhile, p-
H2AX
expression was increased dramatically. Then, we observed that
INPP4B
knockdown inhibited the loss of p-
H2AX
expression after cytarabine removal in
INPP4B
-silenced KG-1 cells, whereas, in control KG-1 cells, the expression of p-
H2AX
was reduced in a time-dependent manner. Next,
INPP4B
knockdown can significantly downregulate ATM expression and subsequently inhibit the activation of ATM downstream targets of p-ATM, p-BRCA1, p-ATR, and p-RAD51. Furthermore, nuclear localization of p65 was inhibited after
INPP4B
knockdown, and reactivation of p65 can rescue the
INPP4B
knockdown-induced inhibition of ATM, p-ATM, p-BRCA1, p-ATR, and p-RAD51. Finally,
INPP4B
expression was positively correlated with ATM expression in AML cells, both
INPP4B
knockdown and KU55933 can significantly sensitize primary myeloid leukemic cells to cytarabine treatment.Collectively, these data suggest that enhanced ATM-dependent DNA repair is involved in resistance to chemotherapy in
INPP4B
high
AML, which could be mediated by p65 nuclear translocation, combination chemotherapy with
INPP4B
or DNA repair pathway inhibition represents a promising strategy in
INPP4B
high
AML.
...
PMID:INPP4B-mediated DNA repair pathway confers resistance to chemotherapy in acute myeloid leukemia. 2734 72